Biocon Biologics

Bengaluru, India
Find alternatives to Biocon Biologics for Cell Therapy →
Program data pending ClinicalTrials.gov matching · Last scored 2026-11-12
75.7
Signal Score
✓ FDA Inspections (7) ○ Clinical Trials ○ SEC Filings ✓ Press (3) ✓ EMA GMP (2) ○ MHRA GMP ✓ HC GMP (4)

Quick Facts: Biocon Biologics

Signal Score
75.7/100 (as of 2026-11-12)
Quality Compliance
93.1/100 — OAI classification at Bengaluru (2022-08-26) — CRITICAL
Headquarters
Bengaluru, India
Modalities
Cell Therapy
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Biocon Biologics

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance 93.1
OAI classification at Bengaluru (2022-08-26) — CRITICAL
Sources: FDA Data Dashboard, EMA EudraGMDP
OAI classification at Bengaluru (2022-08-26) — CRITICAL
FDA Inspections7 on record
Warning Letters0
Last InspectionVoluntary Action Indicated (VAI) (2025-09-03)
EMA GMP Certificates2 on record
Most Recent HC OutcomeCompliant · 2024-07-15
HC Attribution4 company-level
Source: Health Canada Drug and Health Product Inspections Database. Ratings shown in Health Canada's own vocabulary; not equivalent to FDA classifications. Company-level records are attributed by the regulator's published establishment name, not by a verified site identifier. Contains information licensed under the Open Government Licence – Canada.
OAI classification at Bengaluru (2022-08-26) — CRITICAL
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesCell Therapy
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 68.0
Parent company: Biocon
Financial assessment: 68.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Parent company: Biocon
Financial assessment: 68.0/100
Capacity 53.0
1 manufacturing site: Bangalore, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100
Sites: Bangalore, IN
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
Press Signals3 articles (not scored)
1 manufacturing site: Bangalore, IN
Modalities: Cell Therapy
Capacity assessment: 53.0/100

Biocon Biologics FDA Inspection History

2025-09
2024-09
2024-09
2024-07
2024-06
2023-05
2022-08
NAI VAI OAI
Date Site Type 483 citations posted Classification
2025-09-03
Biocon Biologics Limited
Bengaluru Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-09-27
Biocon Limited
Bengaluru Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-09-20
Biocon Limited
Bangalore Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-07-26
Biocon Biologics Limited
Bengaluru Facility-linked
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2024-06-21
Biocon Limited
Paravada Company-level
Drug Quality Assurance Not posted Voluntary Action Indicated (VAI)
2023-05-19
Biocon Limited
Sangareddy Company-level
Drug Quality Assurance Not posted No Action Indicated (NAI)
2022-08-26
Biocon Biologics Limited
Bengaluru Facility-linked
Drug Quality Assurance Not posted Official Action Indicated (OAI)
Source: FDA Data Dashboard · Retrieved Nov 22, 2026

Biocon Biologics EMA GMP Compliance 2 certificates

2026-06
2023-08
Compliant Non-Compliant
Certificate Site Country Inspection Date Status
CRN00H3M2/M13208/00001 Biocon Biologics Ireland Limited Ireland 2026-06-16 COMPLIANT
CRN00H70G/M13208/00001 Biocon Biologics Ireland Limited Ireland 2023-08-01 COMPLIANT
Source: EMA EudraGMDP · Retrieved Nov 22, 2026

Japan-accredited overseas site (PMDA)

biologics · 2 sites

  • Bengaluru, India · Biocon Biologics Limited (Site-1) (2 sites) — biologics · valid to Jan 30, 2030

PMDA accreditation of a foreign manufacturing site is recognition within Japan's regulatory system, not an inspection outcome. PMDA's list covers only manufacturing sites outside Japan, so a company's plants in Japan are not on it. Source: PMDA, list of accredited/registered foreign manufacturers (as of Oct 16, 2026), Public Data License 1.0 (terms)

Hiring Activity 45 open roles Beta

From public job postings on the parent company's careers board, as of Nov 21, 2026. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
45
open roles
5
in manufacturing, quality, PD/MSAT, engineering or regulatory (11%)
Trend from Nov 29, 2026
Tracking started Oct 26, 2026. 30-day change shows after 30 days, 90-day after Jan 28, 2027.
Since Nov 20, 2026: 0 new postings, 125 taken down.
By function
Manufacturing & operations 3
Quality (QA / QC) 1
Process development & MSAT 1
Other (finance, HR, IT, other) 40
By site
Johor
3 mfg/ops · 1 QA/QC · 1 PD/MSAT · 40 other
45
Modality words in job titles
Fill-finish / aseptic1Biologics (cell culture, USP/DSP)1
Latest postings
bahru Team Member MFG E&M Manufacturing & operations · Johor
bahru Team Member Quality Other (finance, HR, IT, other) · Johor
bahru JUNIOR ASSOCIATE Other (finance, HR, IT, other) · Johor
bahru ASSISTANT MANAGER Other (finance, HR, IT, other) · Johor
bahru TRAINEE Other (finance, HR, IT, other) · Johor
bahru SENIOR EXECUTIVE Other (finance, HR, IT, other) · Johor
bahru ASSOCIATE Other (finance, HR, IT, other) · Johor
bahru ASSOCIATE Other (finance, HR, IT, other) · Johor
bahru TRAINEE Other (finance, HR, IT, other) · Johor
bahru Junior Executive Other (finance, HR, IT, other) · Johor
bahru EXECUTIVE Other (finance, HR, IT, other) · Johor
Coverage: read from the parent company's careers board and kept only postings at this business's sites (group board filtered to Biocon Biologics' Johor Bahru (Malaysia) plant; Bengaluru postings are not separable by unit). Roles outside those sites are left out, and some of this unit's roles may be missed. Function groups come mainly from job titles (about 84% match a hand check), and modality words from titles only, so both are approximate.
Source: careers.biocon.com · Checked Nov 21, 2026 · Tracking since Oct 26, 2026

Company Signals 3 articles

Company announcements, not verified evidence. They do not change any score.
regulatory 2026-05-06
Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility - Indian Pharma Post
Biocon Biologics receives 5 procedural observations after US FDA inspection at Bengaluru facility  Indian Pharma Post
regulatory 2026-04-11
India's Biopharma SHAKTI: Syngene, Biocon, Divi's Take Different Routes - Whalesbook
India's Biopharma SHAKTI: Syngene, Biocon, Divi's Take Different Routes  Whalesbook
general 2026-04-11
Biopharma SHAKTI: Kya Syngene, Biocon, Divi's ki hogi Qismat Chamki? Sabka Funda Alag! - Whalesbook
Biopharma SHAKTI: Kya Syngene, Biocon, Divi's ki hogi Qismat Chamki? Sabka Funda Alag!  Whalesbook

Frequently Asked Questions About Biocon Biologics

How many FDA inspections does Biocon Biologics have on record?
CDMO Signal tracks 7 FDA inspections for Biocon Biologics, sourced from the FDA inspection database. See the full inspection history above.
Has Biocon Biologics received an FDA warning letter?
CDMO Signal has no FDA warning letters on record for Biocon Biologics.
Does Biocon Biologics hold EMA or MHRA GMP certificates?
CDMO Signal tracks 2 EMA GMP certificates for Biocon Biologics.
What is Biocon Biologics's CDMO Signal Score?
Biocon Biologics has a Signal Score of 76/100, based on quality, operations, financial stability, and capacity data.
Evaluating Biocon Biologics for a manufacturing program?
Use the free AI matchmaker to compare Biocon Biologics against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Cell Therapy CDMOs →

Similar CDMOs

Syngene International
Bengaluru, India
Signal Score: 80.3
Biologics, Cell Therapy
Intas Pharmaceuticals
Ahmedabad, India
Signal Score: 62.3
Cell Therapy
Bristol Myers Squibb (CGT Mfg)
Bothell, WA · Warren, NJ
Signal Score: 87.0
CAR-T, Cell Therapy
Charles River Laboratories
Newbury Park, CA · Memphis, TN · Keele, UK · Rockville, MD
Signal Score: 86.3
CAR-T, Cell Therapy, Gene Editing, Plasmid, AAV, Lentiviral, ADC
City of Hope (T Cell Manufacturing)
Duarte, CA
Signal Score: 84.0
CAR-T, Cell Therapy

Compare Biocon Biologics with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Biocon Biologics
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.